Skip to main content
. 2020 Jul 14;133(15):1774–1785. doi: 10.1097/CM9.0000000000000917

Figure 2.

Figure 2

MUC1 is a downstream gene of miR-485-5p. (A) Screening for differential miRNAs in HCC tissues by miRNA microarray. (B) The miR-485-5p expression in HCC tissues (n = 15) and corresponding paratumor tissues (n = 15) measured by qRT-PCR. ∗P < 0.001 compared with paratumor tissues. The correlation of MUC1 and miR-485-5p analyzed by Pearson analysis (n = 15, P < 0.01). (C) The complementary regions of MUC1 and miR-485-5p investigated using the bioinformatics tool TargetScan. (D) Luciferase activity was detected after WT-MUC1 or MT-MUC1 cotransfection with NC-miRNA or miR-485-5p mimics for 48 h in HepG2 cells, according to the Lipofectamine 3000 manufacturer's instructions. ∗P < 0.01 compared with NC-miRNA. Western blot and qRT-PCR showed the expressions of MUC1 and miR-485-5p after transfection of (E) miR-485-5p mimics (miR-485-5p: ∗P < 0.001 compared with NC-miRNA group; MUC1: †P < 0.001 compared with NC-miRNA group) or (F) miR-485-5p inhibitor for 48 h in HepG2 cells, according to the Lipofectamine 3000 manufacturer's instructions (miR-485-5p: ∗P < 0.01 compared with NC-miRNA group; MUC1: †P < 0.01 compared with NC-miRNA group). The data in (D–F) are expressed as mean ± standard deviation (n = 3). HCC: Hepatocellular carcinoma; MiR: MicroRNA; MUC1: Mucin 1; MT-MUC1: Mutant-type MUC1; qRT-PCR: Quantitative real-time polymerase chain reaction; WT-MUC1: Wild-type MUC1.